Navigation Links
Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
Date:6/26/2010

ORLANDO, Fla., June 26 /PRNewswire/ -- Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c (HbA1c),(1-4) fasting plasma glucose (FPG)(1-4) and postprandial glucose (PPG).(1,2)  Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 (DPP-4) inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes. The linagliptin data are being presented this week at the 70th Annual American Diabetes Association (ADA) Scientific Sessions in Orlando, Fla.

In the Phase III studies, statistically significant placebo-adjusted changes in HbA1c were observed with linagliptin (5 mg) monotherapy versus placebo (-0.69 percent, p<0.0001)(1) and when used in combination with other commonly-used oral anti-diabetic drugs, including metformin (-0.64 percent, p<0.0001),(2) metformin plus a sulfonylurea (-0.62 percent, p<0.0001),(3) and as initial combination with pioglitazone (-0.51 percent, p<0.0001).(4) Linagliptin therapy also resulted in improvements in beta-cell function.(1) Declining beta-cell function is believed to be a key factor driving the progression of type 2 diabetes.(5)

"It is imperative that blood sugar levels in people with type 2 diabetes are adequately controlled," said Dr. Giora Davidai, executive director & medical leader, medical affairs, cardiovascular & metabolic medicine, Boehringer Ingelheim Pharmaceuticals, Inc. "Uncontrolled blood sugar puts type 2 diabetes patients at a higher risk of developing serious complications like renal impairment and cardiovascular disease, which are very common in patients with type 2 diabetes."


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
2. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
3. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
4. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Boehringer Ingelheim Unveils Diabetes Pipeline
7. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
8. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
9. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
10. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
11. MediPurpose® Announces U.S. Distribution Agreement With Pharmaplast, Egyptian Advanced Wound Care OEM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 /PRNewswire/ ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting ... Under the terms of the collaboration, Foundation ... laboratory component of Foundation Medicine,s FoundationOne® assay at the ...
(Date:10/20/2014)... , 20 de octubre de 2014 /PRNewswire/ ... el campo de la pulmonología intervencional, anunció hoy ... RENEW, casi 3 meses antes de lo programado. El ... exención de dispositivo de investigación (IDE) aprobada por ... el sistema de espiral de reducción de volumen ...
(Date:10/20/2014)... 20, 2014  Luoxis Diagnostics, Inc., a subsidiary ... announced that its academic collaborators will present several ... for its novel RedoxSYS Diagnostic System, a first-in-class ... body in response to injury or illness.  A ... a clinical marker will be presented by ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... 30, 2011 Roche announced today the opening of ... campus in Nutley, N.J. The Roche Center of Excellence ... safety studies, and Phase 1 and 2 clinical studies. ... process potent compounds into medicines for clinical trials. ...
... 30, 2011 ViroPharma Incorporated (NASDAQ: VPHM ... Intellect Neurosciences, Inc. (OTCBB: ILNS) to its clinical stage ... Friedreich,s Ataxia (FA), a rare, hereditary, progressive neurodegenerative disease. ... a naturally occurring, small molecule that has potent anti-oxidant ...
Cached Medicine Technology:Roche Opens New Center of Excellence Facility 2ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia 2ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia 3ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia 4
(Date:10/22/2014)... (PRWEB) October 22, 2014 On Saturday, October ... its fourth annual family health and fitness fair ¡Vive tu ... physical activity and good nutrition for better health and wellness ... which is free and open to the public, will be ... Brownsville, from 9:00 am to 1:00 pm. , “¡Vive ...
(Date:10/22/2014)... For Dr. Iris Hunter, a job is more than ... her life’s mission. Her extensive experience in the nonprofit sector, ... HomeCare, make it clear that Hunter’s mission is to serve ... makes a difference in the lives of others,” Hunter said. ... research, I felt ready to start on this journey as ...
(Date:10/22/2014)... The Louis W. Sullivan Institute ... distribute health information technology innovation to transform quality ... development of six key guiding principles of patient-centered ... These are an expansion of the Institute of ... is respectful of and responsive to individual patient ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... 2014 Lintelus, Inc., an event software ... of Sales, will be speaking on the subject of ... on October 28, at the Holiday Inn in New ... as well as a Tech Demo at 12:45pm, to ... a more engaging event experience. , The Annual Meetings ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
... Suracell Italy; other ... SOUTH ORANGE, N.J., March 3 Suracell, Inc.,( ... age management programs, announces the launch of the ... its cutting edge programs to,the international audience. DNA ...
... at Gala Dinner in San Francisco on June 12, 2008, ... Women,Health Care Executives of Northern California (WHCE) announced today that,Kimberly ... Inc., has been named its 2008 "Woman of the,Year." Popovits ... at the,Carnelian Room atop the Bank of America building in ...
... Access to Local Community, SUNNYVALE, Calif., March ... global leader in the field of radiosurgery,announced today ... second,CyberKnife(R) Robotic Radiosurgery System for its western satellite,location ... will allow those,living in the rural communities easier ...
... American Stock Exchange, HARBIN, China, March 3 ... Board: CSKI; "China Sky" or "the Company"), a,manufacturer, ... in China, announced today the appointment of four ... Chun Fang, Jiang Qi,Feng, Zhao Jie and Qian ...
... Inc. (Amex:,UPI) announced today the presentation of ... PC Neuromodulation System, a proprietary, minimally invasive,nerve ... overactive,bladder (OAB) symptoms, at the Society of ... Tampa, Florida. These retrospective and,observational studies examined ...
... helps make sale of long-term care ... insurance simpler for producers, ... (NYSE: PTA ) has developed a new streamlined pre-,application ... for long-term care insurance (LTCi)., Penn Treaty,s LTCi QuickPass ...
Cached Medicine News:Health News:Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally 2Health News:Women Health Care Executives Names Genomic Health President Kimberly Popovits as 'Woman of the Year' 2Health News:St. Louis University Hospital Purchases Second CyberKnife(R) System 2Health News:St. Louis University Hospital Purchases Second CyberKnife(R) System 3Health News:China Sky One Medical, Inc. Appoints Four Independent Board Members 2Health News:China Sky One Medical, Inc. Appoints Four Independent Board Members 3Health News:China Sky One Medical, Inc. Appoints Four Independent Board Members 4Health News:Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium 2Health News:Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium 3Health News:Penn Treaty Introduces LTCi QuickPass(SM) Program 2
Econo lucae bayonet forceps....
Medpor 2/3 Orbit implants are designed to replace non load bearing bony structures in the orbital area....
... The Medpor Inferior Orbital Rim implant ... projection and is designed to be trimmed ... patient. A small flange allows it to ... the orbital floor. This flange allows easier ...
Flattened points in vertical plane, straight shafts, cross action, round handle....
Medicine Products: